Brain

Nalu Medical, Inc. Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain

Staff January 3, 2024

Proceeds will accelerate commercial growth and expand clinical and health-economic evidence for the innovative Nalu neurostimulation system featuring the revolutionary...

Synchron Appoints Riki Banerjee as Chief Technology Officer

Staff January 3, 2024

NEW YORK--(BUSINESS WIRE)--#BCI--Synchron, the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment,...

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Staff January 3, 2024

Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics...

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

Staff January 3, 2024

Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics...

IRLAB is Granted an End-of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program

Staff January 3, 2024

GOTHENBURG, SWEDEN / ACCESSWIRE / January 3, 2024 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, January 3, 2024 - IRLAB...

Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)

Staff January 2, 2024

- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue...

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Staff January 2, 2024

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug...

Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

Staff January 2, 2024

- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular...

Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met

Staff December 28, 2023

The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical studyBRAINTREE,...

NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

Staff December 27, 2023

NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA...

Algernon Pharmaceuticals Announces Increase to Private Placement

Staff December 27, 2023

VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Staff December 27, 2023

BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class...

IRLAB Extends CEO Appointment

Staff December 27, 2023

GOTHENBURG, SWEDEN / ACCESSWIRE / December 27, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, December 27, 2023 - IRLAB...

U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility

Staff December 23, 2023

Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital...

Todos Medical Announces Insolvency Proceedings in Israel

Staff December 23, 2023

NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, Israel, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd....

FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC

Staff December 22, 2023

TORONTO, ON / ACCESSWIRE / December 22, 2023 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma" or the "Company"),...

IRLAB Increases its Liquidity with a Loan Facility of Up to SEK 55 Million that Extends Financial Runway and Increases Business Opportunities

Staff December 22, 2023

GOTHENBURG, SWEDEN / ACCESSWIRE / December 22, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)(Nasdaq Stockholm:IRLAB A), a company discovering and developing novel...

Brain

Nalu Medical, Inc. Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain

Synchron Appoints Riki Banerjee as Chief Technology Officer

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases

IRLAB is Granted an End-of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program

Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met

NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

Algernon Pharmaceuticals Announces Increase to Private Placement

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

IRLAB Extends CEO Appointment

U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility

Todos Medical Announces Insolvency Proceedings in Israel

FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC

IRLAB Increases its Liquidity with a Loan Facility of Up to SEK 55 Million that Extends Financial Runway and Increases Business Opportunities

IRLAB Receives Grant from The Michael J. Fox Foundation to Support Development of IRL757 for the Treatment of Apathy

IRLAB’s Drug Candidate IRL757 is Phase I Ready

MyndTec Inc. Completes Second Tranche of Non-Brokered Private Placement

UK-Based Vesalic Limited Emerges from Stealth with Landmark Discovery of Potential Non-CNS Driver of Motor Neuron Diseases, including ALS, and Breakthrough Therapeutic and Diagnostic Opportunities

Vesalic Limited identifica un posible impulsor no relacionado con el SNC de la ELA

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

GaraHerb Supplement Facts, Ingredient Label Details, and Product Disclosures: A 2026 Informational Overview of Male Enhancement Supplement Options

Cannabix Technologies announces Non-Brokered LIFE Private Placement

You may have missed